

24 February 2025

**ValiRx PLC**  
**("ValiRx" or the "Company")**

**Conclusion of Evaluation Project**

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update at the conclusion of the Evaluation project from Imperial College London announced on 21 March 2024.

On entering the collaboration agreement with Imperial College London in March 2024, the Company synthesised, tested and profiled drug candidates from the Dual Kinase series in comparison with gold standard therapeutics in a range of tests.

Although initial results showed promise, the development programme is at an early stage, and the Company has decided to return the project to the university researchers for further development, with no further financial commitment from the Company. The parties have agreed to terminate the current collaboration agreement and revert responsibility for maintaining the intellectual property to Imperial College London.

**Mark Eccleston, CEO of ValiRx commented** "Working alongside the Imperial College London team on this project has been an engaging experience, and although we are not in a position to progress with this lead series of molecules at this stage, we look forward to retaining close contact with the team at Imperial to hear further updates on these and other projects which could lead to future agreements."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

**\*\*\* ENDS \*\*\***

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: <https://valirx.com/s/cc8ef3>

For more information, please contact:

<b>Investor questions on this announcement</b>  We encourage all investors to share questions on this announcement via our investor hub	<a href="https://valirx.com/link/Ve96or">https://valirx.com/link/Ve96or</a>
<b>ValiRx plc</b>  Dr Mark Eccleston, CEO	<b>Tel: +44 115 784 0025</b>  <a href="http://www.valirx.com">www.valirx.com</a>  Mark.Eccleston@valirx.com
<b>Cairn Financial Advisers LLP (Nominated Adviser)</b>  Liam Murray / Ludovico Lazzaretti	<b>Tel: +44 (0) 20 7213 0880</b>
<b>Shard Capital Partners LLP (Sole Broker)</b>  Damon Heath	<b>Tel: +44 (0) 20 7186 9000</b>
<b>V Formation (Public Relations)</b>  Lucy Wharton - Senior PR Executive  Sue Carr - Director	<b>+44 (0) 115 787 0206</b>  <a href="http://www.vformation.biz">www.vformation.biz</a>  lucy@vformation.biz  sue@vformation.biz

Subscribe to our news alert service: <https://valirx.com/s/f298d1>

#### Notes for Editors

##### About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: [www.valirx.com](http://www.valirx.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPKDBKDBKDFBB